Safety Evaluation of Oral Sirolimus in the Treatment of Childhood Diseases: A Systematic Review.

Background

Sirolimus, a mammalian target of rapamycin inhibitor, has been widely used in pediatric patients, but the safety of sirolimus in pediatric patients has not been well determined.

Objective

The objective of this study was to systematically evaluate prospective studies reporting the safety of sirolimus in the treatment of childhood diseases.

Methods

The following data were extracted in a standardized manner: study design, demographic characteristics, intervention, and safety outcomes.

Results

In total, 9 studies were included, encompassing 575 patients who received oral sirolimus for at least 6 months. Various adverse events occurred. The most common adverse event was oral mucositis (8.2%, 95% CI: 0.054 to 0.110). Through comparative analysis of the subgroups based on the targeted concentration range, we discovered that many adverse events were significantly higher in the high concentration group (≥10 ng/mL) than in the low concentration group (<10 ng/mL) (p < 0.01). More interestingly, we found that oral mucositis was more frequently reported in children with vascular anomalies than tuberous sclerosis complex.

Conclusions

This study shows that oral sirolimus in the treatment of childhood diseases is safe and reliable. However, sirolimus treatment in the pediatric population should be strictly monitored to reduce the occurrence of serious or fatal adverse events.